Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This article explores the pivotal role of Galectin-1 in enhancing monocyte-mediated inflammation in myeloproliferative neoplasms (MPNs) and highlights its potential as a novel therapeutic target through the TLR4-NF-κB signaling axis.
This article highlights the discovery that TYK2 kinase is a selective therapeutic target in CALR-mutant myeloproliferative neoplasms, with combined TYK2 and JAK2 inhibition offering enhanced efficacy over JAK2 inhibition alone.
Analysis of SEER data from 2000-2021 reveals incidence, survival trends, and demographic disparities in US patients with myeloproliferative neoplasms, highlighting improved outcomes particularly in primary myelofibrosis and areas for furthe
This study evaluates non-invasive biomarkers to differentiate essential thrombocythemia, premyelofibrosis, and overt myelofibrosis, revealing distinct inflammatory and immune profiles and supporting a disease continuum model.
Allogeneic hematopoietic stem cell transplantation offers a potential cure for blast-phase myeloproliferative neoplasms, with one-third of patients achieving long-term survival. Key factors influencing outcomes include TP53 mutations and pe
A large genome-wide analysis identifies multiple genetic loci influencing MPN subtypes and reveals a female-specific variant at CDH22/CD40, enhancing understanding of disease heterogeneity and potential for personalized risk stratification.